Here's Why Aimmune Therapeutics Stock Is Surging Today
Shares of Aimmune Therapeutics (NASDAQ: AIMT), a clinical-stage biotech focused on severe allergic reaction prevention, are jumping after an indirect push forward from the FDA. The regulator released a briefing document ahead of this Friday's advisory committee meeting to discuss the company's only late-stage new drug candidate, and investors are reacting to a welcome lack of surprises. The stock was up 12.4% as of 12:19 p.m. EDT on Wednesday.
The FDA becomes privy to so much proprietary information during the normal course of drug development that nearly all communications between U.S. regulators and biopharmaceutical companies are considered private and not subject to disclosure. Aimmune shares were given a lift today by a lack of surprises in the briefing document that outlines issues the FDA wants to discuss with independent experts before granting Aimmune approval to market AR101 under the brand name Palforzia.
Image source: Getty Images.
Source Fool.com
